Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GEN1042 Monotherapy and Combination Therapy in Advanced Solid Tumors
NCT04083599Phase 2Active, not recruiting
- Sponsor
- Genmab
- Start
- Sep 2019
- Primary completion
- Dec 2025
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 12
01
Overview
Phase 2, open-label trial of tecaginlimab in solid tumor, non-small cell lung cancer (NSCLC), colorectal cancer (CRC) and 3 more (2 arms), sponsored by Genmab. Primary endpoints: Dose-Limiting Toxicities at 21 days and Objective Response Rate. Started Sep 2019; status: active, not recruiting.
02
Drugs
tecaginlimab
03
Conditions
solid tumornon-small cell lung cancer (NSCLC)colorectal cancer (CRC)melanomahead and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT04083599.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04083599.